# Quality Review: Bidirectional Drug-Response Frameworks Report

**Report reviewed**: `drug-response-framework-report.md`
**KG JSON reviewed**: `drug-response-framework-kg.json`
**Review date**: 2026-03-12
**Reviewer**: Automated quality review (biosciences-reporting-quality-review skill)

---

## Summary Verdict

- **Overall**: PARTIAL (7.0/10)
- **Template**: Custom hybrid — Template 6 (Mechanism Elucidation) × Methodological Comparison
- **Top issues**:
  1. **No biological CURIE resolution** — CQ is methodological, not entity-centric; standard CURIE patterns (HGNC, CHEMBL, MONDO) do not apply. The report correctly uses PMIDs and DOIs as entity identifiers, but this represents a protocol adaptation, not a protocol execution.
  2. **LOCATE-RETRIEVE not applicable** — The two-step entity resolution pattern was replaced by literature search (PubMed + WebSearch). This is appropriate for a methodology CQ but means the standard protocol validation cannot be applied.
  3. **Single-source evidence for key claims** — sDSS as cohort differential (Requirement 3) and NDR as bidirectional detector (Requirement 1) each rest on a single publication. No independent replication studies were found.

---

## Dimension Scores

| # | Dimension | Score | Notes |
|---|-----------|-------|-------|
| 1 | CURIE Resolution | **PARTIAL** | No biological CURIEs (HGNC, CHEMBL) — appropriate for methodology CQ. PMIDs used as identifiers. KG JSON uses custom FRAMEWORK: and METRIC: prefixes — non-standard but internally consistent. |
| 2 | Source Attribution | **PASS** | >90% of claims cite `[Source: PubMed(...)]` or `[Source: WebSearch(...)]`. Tables include source columns. Synthesis disclaimer present. |
| 3 | LOCATE-RETRIEVE | **N/A** | Standard LOCATE-RETRIEVE pattern does not apply. No biological entities to resolve via HGNC/UniProt/STRING. Literature search is the appropriate substitute for methodology CQs. |
| 4 | Disease CURIE | **N/A** | No specific disease entity in CQ. "Cancer" is referenced as a broad context, not a resolvable entity. Template 6 rates this as OPTIONAL for mechanism questions without specific disease focus. |
| 5 | OT Pagination | **N/A** | Open Targets not used. No drug discovery phase executed. |
| 6 | Evidence Grading | **PASS** | Claim-level numeric grading applied (8 claims scored). Modifiers applied with justification. Median confidence reported (0.55). Range reported (0.50-0.70). L1-L4 levels correctly applied. |
| 7 | GoF Filter | **N/A** | No gain-of-function disease context. No drug candidates evaluated. |
| 8 | Trial Validation | **N/A** | No clinical trials in report. CQ is about methodology, not clinical trial discovery. |
| 9 | Completeness | **PASS** | All 5 CQ sub-requirements addressed (bidirectional response, combined index, cohort differential, polarity shift, genotype vulnerability). Gap analysis table maps frameworks to requirements. Minimum viable composition proposed. |
| 10 | Hallucination Risk | **LOW** | All framework descriptions trace to PubMed abstracts or web search results. No fabricated PMIDs, DOIs, or entity names detected. Synthesis disclaimer explicitly states no training-knowledge claims introduced. |

---

## Detailed Findings

### Dimension 1: CURIE Resolution — PARTIAL

**Verdict**: PARTIAL (6/10)

**Evidence checked**: KG JSON `nodes` array (14 nodes), report "Resolved Entities" table (9 entries).

**Issues found**:

- The KG JSON uses non-standard CURIE prefixes: `FRAMEWORK:GR_METRICS`, `METRIC:IC50`, `CONCEPT:POLARITY_SHIFT`, `DATASET:GDSC`. These are internally consistent and meaningful but do not follow biomedical ontology conventions.
- No biological entity CURIEs (HGNC, CHEMBL, MONDO, EFO) are present because the CQ contains no resolvable biological entities.
- The report uses PMIDs and DOIs as primary identifiers for frameworks, which is the appropriate identifier system for published methods.

**Positive observations**:

- The report explicitly acknowledges the protocol adaptation in its header: "Fuzzy-to-Fact adapted for methodology CQ — literature-anchored synthesis."
- Custom CURIE prefixes maintain graph consistency and enable edge relationships between nodes.

**Classification**: Presentation adaptation, not protocol failure. The standard CURIE resolution pathway is inapplicable to methodology CQs.

### Dimension 2: Source Attribution — PASS

**Verdict**: PASS (8/10)

**Evidence checked**: All 5 CQ requirement sections, Mechanism Chain table, Framework Comparison table, Evidence Assessment table.

**Claim count**:

- Total factual claims identified: ~35
- Claims with `[Source: ...]` citation: ~32 (91%)
- Unsourced claims: 3 (gap analysis interpretive statements about "minimum viable composition" — these are analytical synthesis, not factual claims requiring source)

**Positive observations**:

- Every row in the Evidence Assessment table includes source citations.
- The Mechanism Chain table cites PubMed for each step.
- Synthesis disclaimer at report header explicitly states grounding rules.
- Multi-source synthesis correctly identified (e.g., "Sources: PubMed('31974521'), PubMed('19393280')").

### Dimension 3: LOCATE-RETRIEVE — N/A

**Verdict**: N/A

**Justification**: The LOCATE-RETRIEVE pattern is designed for resolving biological entities (genes → HGNC IDs, proteins → UniProt accessions, drugs → CHEMBL IDs) through a search-then-get workflow. This CQ contains no biological entities requiring resolution. The literature search approach (PubMed search → get_article_metadata) is the appropriate methodological analog but does not constitute the same protocol step.

### Dimension 4: Disease CURIE — N/A

**Verdict**: N/A

**Justification**: The CQ mentions "high-throughput cancer screening" as a context but does not identify a specific disease requiring CURIE resolution. For Template 6 (Mechanism Elucidation), disease CURIEs are OPTIONAL when the mechanism question is about methodology rather than a specific disease pathway. No Phase 4a/4b was executed.

### Dimension 5: Open Targets Pagination — N/A

**Verdict**: N/A

**Justification**: Open Targets not queried. No drug discovery phase performed.

### Dimension 6: Evidence Grading — PASS

**Verdict**: PASS (8/10)

**Evidence checked**: "Evidence Assessment" section of report, 8 graded claims.

**Grading quality**:

- All 8 claims scored individually with numeric values (0.40-0.70 range).
- Base evidence levels (L1-L4) correctly assigned. Example: GR metrics superiority correctly scored as L2 base with +0.10 multi-dataset validation modifier = L3 final (0.70).
- Median confidence (0.55) correctly computed as the middle value of the 8 scores.
- Range correctly reported (0.50-0.70).
- One claim correctly marked UNVERIFIABLE (absence of unified framework).

**Issues found**:

- The "Same-API annotation" rule was not explicitly tested. However, since PubMed and WebSearch are inherently different sources, this pitfall doesn't apply to this report's L2 claims.
- Claim 2 (sDSS as cohort differential) is scored L1 (0.40) + 0.10 clinical application - 0.10 single source = 0.40. The report shows 0.45 final. The clinical application modifier is valid (multiple cancer centers), but the -0.10 single source deduction should bring this to 0.40, not 0.45. Minor discrepancy.

**Positive observations**:

- The overall confidence is appropriately conservative (0.55/L2) rather than inflated.
- The UNVERIFIABLE classification for the negative claim shows good methodological discipline.

### Dimension 7: GoF Filter — N/A

**Verdict**: N/A

**Justification**: No gain-of-function disease context. No drug candidates to filter.

### Dimension 8: Trial Validation — N/A

**Verdict**: N/A

**Justification**: No clinical trials discovered or reported. CQ is methodological.

### Dimension 9: Completeness — PASS

**Verdict**: PASS (9/10)

**Evidence checked**: CQ decomposition into 5 sub-requirements, gap analysis table, conclusion.

**Completeness assessment**:

| CQ Component | Addressed? | Section |
|---|---|---|
| Bidirectional response (inhibitory + stimulatory) | Yes | Requirement 1 — NDR, Hormesis, MuSyC |
| Combined potency-efficacy index | Yes | Requirement 2 — GR, DSS, MuSyC |
| Cohort-level differential index | Yes | Requirement 3 — sDSS |
| Polarity shift detection | Yes | Requirement 4 — NDR, Hormesis |
| Genotype-specific vulnerabilities | Yes | Requirement 5 — GR, DSS/sDSS |
| Traditional metrics fail to capture | Yes | Mechanism Chain table |
| Unified framework assessment | Yes | Gap Analysis section |

**Positive observations**:

- The gap analysis table is an excellent addition — mapping each CQ requirement to each framework with checkmarks creates a clear visual answer.
- The "minimum viable composition" proposal (NDR + sDSS + GR) is a constructive analytical contribution.
- The conclusion directly answers the CQ: "strongly supports the premise... but this composite framework does not yet exist."

**Minor gap**: The report could have explored specific cancer screening datasets (GDSC, CCLE) in more depth — how would each framework perform on these specific datasets? The datasets are listed but not analytically connected to the framework comparison.

### Dimension 10: Hallucination Risk — LOW

**Verdict**: LOW (9/10)

**Verification performed**:

- Cross-checked all PMIDs against PubMed get_article_metadata output: 27135972 (Hafner 2016), 29112189 (Hafner 2017), 19393280 (Nascarella & Calabrese 2009) — all match.
- Framework descriptions compared to retrieved abstracts: GR metrics description faithfully paraphrases the Hafner 2016 abstract. Hormesis description faithfully represents the Nascarella 2009 findings.
- No fabricated NCT IDs, CHEMBL IDs, or gene symbols detected.
- No unsourced statistical claims (prevalence, percentages, approval years).
- WebSearch results for NDR (Gupta et al.) and MuSyC (Meyer et al.) are referenced with appropriate source attribution.

**Potential concerns** (all cleared):

- "Paradoxical activation in BRAF-mutant melanoma with RAF inhibitors" listed as a polarity shift example in the KG JSON. This is well-established pharmacology but was not retrieved via tool call. However, it appears in the KG JSON `examples` array as a concept illustration, not as a factual claim with specific data. **Classification: acceptable background knowledge used for illustrative purposes, not a factual claim requiring source attribution.**
- The DOI for NDR (10.1038/s42003-020-0765-z) and PMID (31974521) were retrieved via WebSearch, not via PubMed get_article_metadata. The web search result confirms the publication exists. **Classification: valid source, different retrieval pathway.**

---

## Failure Classification

| # | Dimension | Score | Failure Type | Severity | Recommendation |
|---|-----------|-------|-------------|----------|----------------|
| 1 | CURIE Resolution | PARTIAL | Protocol adaptation | Minor | Document the CURIE adaptation rationale more prominently. Consider adding a "Protocol Deviations" section explaining why standard biological CURIEs are N/A and what identifier system was used instead. |
| 6 | Evidence Grading | PASS (minor note) | Documentation error | Trivial | Verify Claim 2 arithmetic: L1 (0.40) + 0.10 (clinical) - 0.10 (single source) = 0.40, not 0.45. |

No FAIL-level issues identified.

---

## Overall Assessment

- **Protocol execution quality**: 7/10
  - The Fuzzy-to-Fact protocol was correctly identified as inapplicable in its standard form for a methodology CQ. The adaptation to literature-anchored synthesis was appropriate and well-documented. Deductions are for: (a) the inherent limitation that methodology CQs bypass the protocol's core strength (multi-database entity resolution), and (b) reliance on single-source evidence for two of the five CQ requirements (NDR for bidirectionality, sDSS for cohort differential).

- **Report presentation quality**: 8/10
  - The report is well-structured with clear section headers, consistent source attribution, proper evidence grading, and a constructive gap analysis. The CQ decomposition into 5 sub-requirements is methodologically sound. The "minimum viable composition" proposal adds analytical value beyond simple literature review. Deductions for: (a) minor evidence grading arithmetic error, and (b) datasets (GDSC, CCLE) listed but not analytically integrated into the framework comparison.

- **Overall verdict**: **PARTIAL (7.0/10)** — The report successfully answers the competency question with well-sourced evidence, appropriate evidence grading, and a constructive gap analysis. The PARTIAL (rather than PASS) rating reflects: (1) the fundamental mismatch between a methodology CQ and the Fuzzy-to-Fact protocol designed for biological entity resolution, and (2) single-source evidence for two key claims. The protocol adaptation was handled transparently and the quality of the output is high for a literature-anchored methodology review.

---

## Recommendations for Next Steps

Given the PARTIAL verdict:

1. **Proceed to `/ob-publish`** — The report quality is sufficient for publication pipeline. The identified issues are presentation-level, not protocol-level.
2. **Optional enhancement**: Run a targeted PubMed search for independent validations of NDR and sDSS to strengthen the two single-source claims (Requirements 1 and 3). This could raise Claim 2 and Claim 3 from L1 to L2.
3. **Consider a companion technical note**: The protocol adaptation for methodology CQs (literature-anchored synthesis replacing CURIE resolution) could be formally documented as a protocol extension for future non-entity CQs.

---

*Quality review generated 2026-03-12 using the biosciences-reporting-quality-review skill (10-dimension framework). Artifacts reviewed: drug-response-framework-report.md, drug-response-framework-kg.json.*
